Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celcuity Inc CELC

Healthcare Biotechnology
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes... see more

Recent & Breaking News (NDAQ:CELC)

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

GlobeNewswire April 4, 2024

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 27, 2024

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

GlobeNewswire March 20, 2024

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

GlobeNewswire March 6, 2024

Celcuity to Participate in Cowen's 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

GlobeNewswire February 22, 2024

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

GlobeNewswire February 20, 2024

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

GlobeNewswire December 6, 2023

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

GlobeNewswire December 1, 2023

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

GlobeNewswire November 22, 2023

Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire November 13, 2023

Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call

GlobeNewswire November 6, 2023

Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences

GlobeNewswire November 1, 2023

Celcuity Inc. Announces $50 Million Private Placement

Accesswire October 18, 2023

Celcuity to Host Virtual Science Day for Investors

GlobeNewswire September 7, 2023

Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial

GlobeNewswire August 22, 2023

Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer

GlobeNewswire August 22, 2023

Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

GlobeNewswire August 10, 2023

Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call

GlobeNewswire August 3, 2023

Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023

GlobeNewswire July 31, 2023